Thrombophilia screening: Difference between revisions

Jump to navigation Jump to search
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Thrombophilia}}
{{Thrombophilia}}
{{CMG}} {{AE}} {{asiri}}
{{CMG}} {{AE}} {{asiri}} {{JK}}


==Overview==
==Overview==
Line 7: Line 7:


==Screening==
==Screening==
*The American Society of Hematology, British Committee for Standards in Hematology, and the British Society for Hematology have proposed the following recommendations for the screening of '''inherited thrombophilias''' as follows in '''Table 1''':<ref name="pmid24319155">{{cite journal| author=Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A et al.| title=The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question. | journal=Hematology Am Soc Hematol Educ Program | year= 2013 | volume= 2013 | issue= | pages= 9-14 | pmid=24319155 | doi=10.1182/asheducation-2013.1.9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24319155 }} </ref> <ref name="pmid21340752">{{cite journal| author=Middeldorp S| title=Evidence-based approach to thrombophilia testing. | journal=J Thromb Thrombolysis | year= 2011 | volume= 31 | issue= 3 | pages= 275-81 | pmid=21340752 | doi=10.1007/s11239-011-0572-y | pmc=3056012 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21340752 }} </ref> <ref name="pmid26780744">{{cite journal| author=Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M et al.| title=Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. | journal=J Thromb Thrombolysis | year= 2016 | volume= 41 | issue= 1 | pages= 154-64 | pmid=26780744 | doi=10.1007/s11239-015-1316-1 | pmc=4715840 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26780744  }} </ref>  
*The American Society of Hematology, British Committee for Standards in Hematology, and the British Society for Hematology have proposed the following recommendations for the screening of '''inherited thrombophilias''' as follows in '''Table 1''':<ref name="pmid21340752">{{cite journal| author=Middeldorp S| title=Evidence-based approach to thrombophilia testing. | journal=J Thromb Thrombolysis | year= 2011 | volume= 31 | issue= 3 | pages= 275-81 | pmid=21340752 | doi=10.1007/s11239-011-0572-y | pmc=3056012 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21340752 }} </ref> <ref name="pmid24319155">{{cite journal| author=Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A et al.| title=The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question. | journal=Hematology Am Soc Hematol Educ Program | year= 2013 | volume= 2013 | issue= | pages= 9-14 | pmid=24319155 | doi=10.1182/asheducation-2013.1.9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24319155 }} </ref> <ref name="pmid26780744">{{cite journal| author=Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M et al.| title=Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. | journal=J Thromb Thrombolysis | year= 2016 | volume= 41 | issue= 1 | pages= 154-64 | pmid=26780744 | doi=10.1007/s11239-015-1316-1 | pmc=4715840 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26780744  }} </ref>  


{| class="wikitable"
{| class="wikitable"
Line 15: Line 15:
|  
|  
*'''Asymptomatic screening''': [[First degree relative]]s of patients with [[homozygosity]] for [[Factor V Leiden]], [[antithrombin deficiency]], [[Protein C deficiency|Protein C]] or [[Protein S deficiency]] and anticipated hormone therapy or pregnancy  
*'''Asymptomatic screening''': [[First degree relative]]s of patients with [[homozygosity]] for [[Factor V Leiden]], [[antithrombin deficiency]], [[Protein C deficiency|Protein C]] or [[Protein S deficiency]] and anticipated hormone therapy or pregnancy  
*''Symptomatic screening''': Patients presenting with a first episode of acute [[thrombosis]].  
*'''Symptomatic screening''': Young patients (under 50) without any other identifiable risk factors such as oral contraceptive use or recent surgery; and patients with recurrent venous thrombosis <ref name="TraniLawson2007">{{cite journal|last1=Trani|first1=Jose L.|last2=Lawson|first2=Jeffrey H.|title=HYPERCOAGULABLE STATES ASSOCIATED WITH CHRONIC VENOUS INSUFFICIENCY|year=2007|pages=55–65|doi=10.1016/B978-012373565-2.50009-9}}</ref>
||  
||  
*Adult patients with venous [[thrombosis]] in the setting of major transient risk factors such as [[surgery]], [[trauma]], or prolonged [[immobility]].
*Adult patients with venous [[thrombosis]] in the setting of major transient risk factors such as [[surgery]], [[trauma]], or prolonged [[immobility]].
|}
|}


*Steps:
*'''Steps to be taken before pursuing the screening tests are as follows:'''
**Family members (and patients) should receive genetic counseling before genetic testing, and such testing should be performed only after informed consent is obtained.
**Family members and patients should receive '''genetic counseling''' before genetic testing; and '''informed consent''' must be obtained before conducting such testing procedures.
**Counseling should include the reasons for testing, such as the potential for avoiding clinical thrombosis by risk factor modification or prophylaxis (both for the family member as well as his or her children), and the reasons for not testing, such as stigmatization and mental anguish, the potential effect on obtaining personal health insurance or employment, and the possibility of nonpaternity.
**Counseling should include the following: <ref name="pmid15081560">{{cite journal| author=Bank I, Scavenius MP, Büller HR, Middeldorp S| title=Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. | journal=Thromb Res | year= 2004 | volume= 113 | issue= 1 | pages= 7-12 | pmid=15081560 | doi=10.1016/j.thromres.2004.02.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15081560  }} </ref>
 
***'''Reasons for testing''': Higher potential for avoiding the clinical thrombosis by risk factor modification or prophylactic measures for both the family member their children,
*Deep venous thrombosis/chronic venous insufficiency: Despite the high incidence of thrombophilia in patients who present with a new deep venous thrombosis as well as in patients who ultimately progress to develop venous ulceration, prolonged anticoagulation is not recommended. Screening patients for thrombophilia conditions should be undertaken only under specific circumstances. Young patients (under 50) without any other identifiable risk factors, such as oral contraceptive use or recent surgery; patients with a family history of deep venous thrombosis; and patients with recurrent venous thrombosis should all receive screening for a hypercoagulable state should receive additional screening consideration. Patients who have more than one thrombophilia condition identified by screening may benefit from prolonged anticoagulation.
***'''Reasons for not testing''': Stigmatization and mental anguish, the potential effect on obtaining personal health insurance or employment, and the possibility of nonpaternity.


==References==
==References==

Latest revision as of 18:21, 13 March 2021

Thrombophilia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombophilia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombophilia screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombophilia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombophilia screening

CDC on Thrombophilia screening

Thrombophilia screening in the news

Blogs on Thrombophilia screening

Directions to Hospitals Treating Thrombophilia

Risk calculators and risk factors for Thrombophilia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Asiri Ediriwickrema, M.D., M.H.S. [2] Jaspinder Kaur, MBBS[3]

Overview

In general, screening for inherited thrombophilias is controversial and should be performed in the appropriate clinical context.[1]According to the American Society of Hematology, screening for inherited thrombophilias is not recommended in adult patients with venous thrombosis in the setting of major transient risk factors which include surgery, trauma, or prolonged immobility.[2] However, patients who have significant risk factors, including a positive family history or concurrent treatment with hormonal therapies, should seek expert consultation.

Screening

  • The American Society of Hematology, British Committee for Standards in Hematology, and the British Society for Hematology have proposed the following recommendations for the screening of inherited thrombophilias as follows in Table 1:[1] [2] [3]
Screening recommended No screening recommended
  • Steps to be taken before pursuing the screening tests are as follows:
    • Family members and patients should receive genetic counseling before genetic testing; and informed consent must be obtained before conducting such testing procedures.
    • Counseling should include the following: [5]
      • Reasons for testing: Higher potential for avoiding the clinical thrombosis by risk factor modification or prophylactic measures for both the family member their children,
      • Reasons for not testing: Stigmatization and mental anguish, the potential effect on obtaining personal health insurance or employment, and the possibility of nonpaternity.

References

  1. 1.0 1.1 Middeldorp S (2011). "Evidence-based approach to thrombophilia testing". J Thromb Thrombolysis. 31 (3): 275–81. doi:10.1007/s11239-011-0572-y. PMC 3056012. PMID 21340752.
  2. 2.0 2.1 Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A; et al. (2013). "The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question". Hematology Am Soc Hematol Educ Program. 2013: 9–14. doi:10.1182/asheducation-2013.1.9. PMID 24319155.
  3. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M; et al. (2016). "Guidance for the evaluation and treatment of hereditary and acquired thrombophilia". J Thromb Thrombolysis. 41 (1): 154–64. doi:10.1007/s11239-015-1316-1. PMC 4715840. PMID 26780744.
  4. Trani, Jose L.; Lawson, Jeffrey H. (2007). "HYPERCOAGULABLE STATES ASSOCIATED WITH CHRONIC VENOUS INSUFFICIENCY": 55–65. doi:10.1016/B978-012373565-2.50009-9.
  5. Bank I, Scavenius MP, Büller HR, Middeldorp S (2004). "Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice". Thromb Res. 113 (1): 7–12. doi:10.1016/j.thromres.2004.02.002. PMID 15081560.

Template:WH Template:WS